Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Yue Shentu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mahmut Gümüş(Istanbul Medeniyet University), Bárbara Hermes(Klinikum im Friedrichshain), Julien Mazières(Université Toulouse III - Paul Sabatier), Ying Cheng(Jilin Province Tumor Hospital), Alexander Luft(Leningrad Regional Cancer Center), Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Ali Tafreshi, Shunichi Sugawara(Sendai Kousei Hospital), Balázs Halmos(Montefiore Medical Center), Silvia Novello(University of Turin), Andrea Fülöp(Országos Korányi Tbc és Pulmonológiai Intézet), Filiz Çay Şenler
Cited by 121
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k